TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06484829
Drug: Purinostat Mesylate 6 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
Study: NCT06484829
Drug: Purinostat Mesylate 8.4 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
Study: NCT05264649
Drug: Guizhi-Shaoyao-Zhimu decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients consumed GZSD (4g paper bagged medicine) three times per day (total daily dose was 12 g/day) continuously during the 6-week intervention period.
Study: NCT05969119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
Study: NCT05132088
Drug: placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
Study: NCT06223269
Drug: Skin Xenotransplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area.
Study: NCT00000811
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05359835
Drug: Calcium DTPA and Zinc DTPA
Normalized name: zinc-DTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
Study: NCT04137978
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
Study: NCT05899621
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT05899621
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06479811
Drug: [203Pb]VMT-alpha-NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[203Pb\]VMT-alpha-NET will be given IV 7 days prior to \[212Pb\]VMT-alpha-NET.
Study: NCT06479811
Drug: [212Pb]VMT-alpha-NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion. One cycle is 8 weeks.
Study: NCT05612035
Drug: MK-5475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5475 380 µg administered as dry powder inhalation once daily.
Study: NCT05612035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as dry powder inhalation once daily.
Study: NCT06516965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06127407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided as tablets, taken orally once daily.
Study: NCT06220604
Drug: JNJ-77242113 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 matching placebo will be administered orally.
Study: NCT05789056
Drug: QRX003, 4% Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Study: NCT06496854
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg ibuprofen, Nonsteroidal anti-inflammatory drug to treat pain
Study: NCT05999513
Drug: casdatifan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06200168
Drug: Standard antiemetic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
Study: NCT06200168
Drug: Standard antiemetic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
Study: NCT05223868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet will be administered orally.
Study: NCT05814367
Drug: Blink® Tears eye drops in a multidose bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control
Study: NCT06094842
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06204614
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be placed in reservoir 1 of the implantable microdevice.
Study: NCT06204614
Drug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
Study: NCT06204614
Drug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
Study: NCT05249634
Drug: Jatenzo Pill
Normalized name: Jatenzo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet daily
Study: NCT01048983
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
Study: NCT06411210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo.
Study: NCT05483010
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin is commercially available.
Study: NCT04864392
Drug: LNA043 Dosing Regimen A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection to the knee
Study: NCT04864392
Drug: LNA043 Dosing Regimen B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection to the knee
Study: NCT04864392
Drug: LNA043 Dosing Regimen C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection to the knee
Study: NCT04864392
Drug: LNA043 Dosing Regimen D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection to the knee
Study: NCT04864392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection to the knee
Study: NCT05520775
Drug: Sham/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham subcutaneous injection
Study: NCT04544189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg by mouth once daily, in a 28-day cycle
Study: NCT04746235
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05116865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT05657132
Drug: Meta paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
Study: NCT06293625
Drug: Folfox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.
Study: NCT05928858
Drug: Premixed Bio-ceramic MTA
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
Study: NCT05928858
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
Study: NCT05106153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally as per assigned treatment sequence.
Study: NCT04911543
Drug: [18F]-JNJ-70099731
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]JNJ-70099731 injection will be administered intravenously.
Study: NCT06414759
Drug: IV Loop Diuretics
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.
Study: NCT05513950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of a physiological solution as placebo.
Study: NCT05350774
Drug: IV immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
Study: NCT06137118
Drug: AZD0486
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product administered via intravenous infusion.
Study: NCT04868981
Drug: Matching Placebos for GST-HG141 tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
Study: NCT05757869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian matching milvexian placebo will be administered orally.
Study: NCT04891757
Drug: FHD-286
Approvals — FDA: no, EMA: no, PMDA: no
Description: FHD-286 administered orally
Study: NCT06442462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05286008
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study: NCT05885841
Drug: XTR004
Approvals — FDA: no, EMA: no, PMDA: no
Description: At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.
Study: NCT05215418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive oral capsule
Study: NCT05127590
Drug: RBN-2397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
Study: NCT05393271
Drug: VH4011499
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4011499 will be administered.
Study: NCT05393271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06312748
Drug: Placebo for L-Citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Citrulline-matched Placebo tablet
Study: NCT06312748
Drug: Placebo for BH4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BH4-matched Placebo
Study: NCT05250973
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered either orally or IV.
Study: NCT05012397
Drug: RAIN-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
Study: NCT05512754
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg tablet
Study: NCT06636786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablets taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
Study: NCT05312879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT05173714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
Study: NCT05788276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablets
Study: NCT05740657
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drugs were administered in the course of a surgery or for pain management.
Study: NCT06255847
Drug: Pomalidomide, cyclophosphamide combined with dexametha
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
Study: NCT06699849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume and regimen matched to CSL899 will be administered.
Study: NCT06313983
Drug: Lapatinib+Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take the pills according to the instructions
Study: NCT05233722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 800 mg of calcium tablets
Study: NCT04844450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously.
Study: NCT06462612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules administered orally, once daily
Study: NCT04959825
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
Study: NCT06314490
Drug: nL-SCN2A-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antisense oligonucleotide
Study: NCT05973773
Drug: TAS6417
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT05747924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via intravenous (IV) infusion
Study: NCT01021163
Drug: N-acetylcysteine, saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
Study: NCT03944902
Drug: Cohort 2: Dose Escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
Study: NCT05818995
Drug: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
Study: NCT05626478
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
Study: NCT05626478
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
Study: NCT05626478
Drug: Prolensa 0.07% Ophthalmic Solution
Normalized name: Prolensa 0.07% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
Study: NCT06475781
Drug: Mirivadelgat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective aldehyde dehydrogenase 2 (ALDH2) activator
Study: NCT06475781
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06385275
Drug: K1 1000 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill daily for 4 weeks.
Study: NCT06080490
Drug: TAC C/D ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of TAC according to possible influencing factors
Study: NCT06104124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05649722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo inhalation using a capsule-based dry powder inhaler device.
Study: NCT06226883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (identical appearance to MORF-057) administered orally.
Study: NCT03652870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose and magnesium stearate tablet to be used as a placebo.
Study: NCT06265584
Drug: ATG dosing platform when combined with standard tacrolimus and mini methotrexate
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day -8, you will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). You will receive a steroids 3 hours before every ATG infusion. On day -7, you will receive a small dose of ATG as an intravenous (IV) infusion. ATG will be repeated on days -6, -5 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -7 to -3 as daily IV infusions. Melphalan, another routine transplant chemotherapy will be given on day -4 as IV infusion. Tacrolimus (standard immune suppression agent) will start on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate is another standard immune suppression medication which is given IV on day +1, +3, +6, and +11 post-transplant. We plan to draw blood on days -4,, -1, +3, +7, and +14 to measure ATG levels.
Study: NCT05537220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, participants will be given about 10-months supply of placebo, with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, efficacy and safety assessments will be done and drug reconciliation will occur. At baseline, M9, M18, M27, and M36 participants will be given another 10-month supply of placebo.
Study: NCT06706076
Drug: BH-30643
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
Study: NCT06556563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
Study: NCT05675410
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05675410
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05675410
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05564390
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06088654
Drug: IPH6501
Approvals — FDA: no, EMA: no, PMDA: no
Description: phase 1 (dose finding) and phase 2 (dose expansion)
Study: NCT06445959
Drug: Decitabine/cedazuridine
Normalized name: decitabine/cedazuridine 35 mg-100 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO